Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial.

Eur Heart J · 2026 · PMC13318417 · PMID 40884558

Europe PMC DOI

hedged sentence

0.1350

closest p · 2.7× alpha

0.1350

boldest claim

The sentences

did not reach statistical significanceP = 0.135not close (p > 0.1)

Additionally, participants receiving an inclisiran-based treatment strategy vs ioLLT also experienced numerically fewer days with pain; however, this difference did not reach statistical significance (198.63 vs 214.51; OR 0.93, 95% CI: 0.81, 1.06, P = 0.135; Supplementary data online , Figure S3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.